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Primary signet ring cell carcinoma of the urinary bladder is a rare and aggressive histologic subtype of
adenocarcinoma. In general, this tumor occurs in the middle age, and clinical presentation does not differ
from transitional cell carcinomas. The prognosis is often poor, given the advanced stage at diagnosis. To
our knowledge, <100 cases of signet ring cell adenocarcinoma of the urinary bladder have been reported.
We report 2 cases with bladder linitis plastica primitive, and we draw attention to its pathologic, ana-
tomoclinical, and evolution speciﬁcity to optimize its therapeutic management.
 2014 The Authors. Published by Elsevier Inc. All rights reserved.Introduction
Primary signet ring cell adenocarcinoma of the urinary bladder,
also called linitis plastica urinary bladder, is rare, accounting for
only 0.24% of all malignant tumors of the urinary bladder.1
Case presentation
Case 1
A 72-year-old patient consulted for intermittent painless total
gross hematuria, urgency, and pollakiuria. The medical and familial
histories were unremarkable. Physical examination was normal.
The abdominal and pelvic ultrasound showed a bilateral hydro-
ureteronephrosis with thickening of the urinary bladder wall.
Cystoscopy visualized a solid mass in the left-side wall of the uri-
nary bladder. Histologic examination of cystoscopic biopsy showed
a proliferation of round-cell aspect of signet ring. An immunohis-
tochemical study demonstrated positivity for cytokeratin 7 andBY-NC-ND license (http://
a).
Published by Elsevier Inc. All righnegativity for cytokeratin 20. The diagnosis of signet ring cell
adenocarcinoma of the bladder was established. Abdominal
computed tomography (CT) showed no locoregional lymph nodes,
metastases, or a primary tumor in other abdominal or pelvic organs.
We performed a complete gastrointestinal endoscopic evalua-
tion to exclude an extravesical primary tumor site, but no other
primary site was found. The tumor was therefore treated as a pri-
mary signet ring cell carcinoma (SRCC) of the urinary bladder. The
patient underwent a radical cystoprostatectomy. The intraoperative
examination found a budding tumor inserted to the left-side wall.
Histologic examination concluded to a signet ring cell adenocarci-
noma with a colloid component estimated about 40%. The tumor
was invasive; it extended into the perivesical fat with carcinoma-
tous lymphangitis and nerve sheathing perished (Fig. 1).
Surgical resection margins were free of tumor cells. The tumor
was classiﬁed pT3N0M0. The patient had no adjuvant treatment.
The patient consulted again after 16 months for hematuria and
perineal pain. Endoscopy showed stenosis of the anterior urethra
and the biopsy conﬁrmed tumor relapse in the urethra. Radio-
therapy at a dose of 64 Gy was delivered: the ﬁrst dose of 44 Gy at 5
fractions of 2 Gy/wk in the pelvis and then an additional 20 Gy in a
limited volume in the urinary bladder. The patient was followed up
every 6 months, and a thoracoabdominal CT scan was done every
6 months. The patient has radiological stability and kept a
preserved quality of life after 3 years of follow-up.ts reserved.
Figure 1. Histopathology of the bladder lesion showing multiple signet ring cells
(hematoxylin-eosin 200).
Figure 2. Neoplastic cells in the ascitic ﬂuid.
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A 64-year-old patient without medical history consulted with a
history of 2months of total hematuria. Pelvic ultrasound showed an
inﬁltrating mass in the posterolateral wall of the urinary bladder
associated with a left hydroureteronephrosis. Cystoscopy showed a
pseudopolypoid mass on the left posterolateral urinary bladder.
Endoscopic resection of the tumor was performed. Pathologic ex-
amination found a poorly differentiated invasive signet ring cell
adenocarcinoma. An abdominal CT scan showed a large effusion
occupying the entire abdomen and peritoneal cavity without evi-
dence of peritoneal carcinomatosis.
The digestive exploration (gastroduodenoscopy and colonos-
copy) showed no suspicious location. The evolution was marked by
the appearance of ascites. Cytologic analysis of the peritoneal ﬂuid
revealed the presence of neoplastic cells (Fig. 2).
Palliative chemotherapy has been proposed but not performed
because of the deterioration in the general condition of the patient.
Hewas followed in the palliative care consultation. The patient died
5 months after diagnosis.
Discussion
Primitive bladder adenocarcinoma accounts for only 0.5%-2% of
all primary malignant tumors of the bladder.1 Most adenocarci-
nomas of the urinary bladder result from direct extension from
adjacent organs (eg, colon, prostate). Rarely, there can bemetastatic
spread to the bladder of SRCC originating in another organ.2 The
variant signet ring cell is a poorly differentiated form, is excep-
tionally described, and its incidence is about 0.24% of bladder
cancers.2
Hematuria, which was the reason for consultation in all our
patients, is the most common clinical presentation. Other symp-
toms that have been reported are dysuria, pollakiuria, and urinary
incontinence or retention.3
It is essential to distinguish this carcinoma from metastases as
different therapeutic strategies are often necessary. Primary SRCC of
the urinary bladder has the same histology as that of the gastro-
intestinal tract, breast, lung, and prostate; therefore, further eval-
uations for other primary sites are mandatory to exclude
metastasis.4 In our case, the gastrointestinal evaluation includedesophagogastroduodenoscopy and colonoscopy, but we found no
other tumor lesions. The histologic diagnosis was based on the
presence of signet ring cells ﬁlled with cytoplasmic mucus-
containing vacuoles compressing and displacing the nucleus into
a peripheral crescent alongside the cell wall. The component signet
ring cells are variable; it is >75% in almost half the cases.5 Our ﬁrst
case was an invasive tumor, which extended to the perivesical fat.
Indeed, the insidious progression of this entity explains the local
character already advanced at diagnosis. At the time of diagnosis,
about 25% of patients have distant metastases and approximately
50% have stage IV disease.6
Primary signet ring cell carcinoma of the urinary bladder has an
ominous prognosis as it is diagnosed at an advanced stage. The
treatment is surgical and consists of an early radical cystectomy.
Resection is often incomplete with no clear margins on the spec-
imen.7 Considering the rarity of this histologic type of tumor, there
is no consensus regarding the management after surgical care.
Chemotherapy and radiation therapy are discussed. Adjuvant
chemotherapy with 5-ﬂuorouracil associated with adriablastin or
bleomycin seems to give favorable responses, by analogy with
stomach plastic linitis.8 Our second patient had no palliative
chemotherapy because of altered general condition.Conclusion
The primary SRCC of the urinary bladder is a rare and aggressive
tumor; the histologic type justiﬁes a surgical strategy associated
with a multidisciplinary approach. Prognosis is poor although some
patients may beneﬁt from surgical resection. Adjuvant chemo-
therapy should be discussed even if consensual attitude has not
been deﬁned.References
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